Lidocaine Hydrochloride Injection, Solution
Product Images NDC 0409-9137

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lidocaine Hydrochloride (NDC 0409-9137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Lidocaine Hydrochloride (Lidocaine Hydrochloride 01)

FDA Label Image

Logo (Lidocaine Hydrochloride 02)

FDA Label Image

Label Ndc 0409-4903-34 (Lidocaine Hydrochloride 03)

This is a description of a pharmaceutical product called ZeLidocaine. It contains 100 mg/mL (20 mg/ml) Lidocaine HCI in a 5 mL vial. This product is sterile, non-pyrogenic, and is intended for use in the treatment of cardiac arrhythmias. The lot number, expiration date, and NDC number are provided. The brand is distributed by Hospira Inc. and contains no preservatives. Renal and hepatic function should be monitored before use.*

FDA Label Image

Principal Display Panel (100 mg/5 mL Syringe Carton)

This is an instruction manual for the aseptic technique required to inject medication from a specific vial. The handle and assemble the vial with caution and in sterile conditions. The purpose of the medication is to treat intravenous cardiac arrhythmias. The manual also includes instructions on accessing the needle and applying gentle pressure to initiate liquid flow from the vial. The product was manufactured in Spain by Hospira, Inc.*

FDA Label Image

Label Ndc 0409-4904-34 (Lidocaine Hydrochloride 05)

This is a description of a 1% Lidocaine HCI Injection, USP with a quantity of 5mL in a single-dose, provided without preservatives, and available through NDC MOS-ARSXM-P. For dosage information, reference the insert included. It is sterile, nonpyrogenic and used for cardiac arrhythmias. The product is manufactured in the United States by Hospira, Inc., Hospira Lake Forest.*

FDA Label Image

Principal Display Panel (50 mg/5 mL Syringe Carton)

FDA Label Image

Principal Display Panel (20 mg/mL Syringe Label)

2% Lidocaine HCI injection is a medication consisting of 100mg of Lidocaine HCI in 5mL of solution (20mg/mL). It is intended for intravenous use to treat ventricular arrhythmias. This medication is distributed by Hospira, Inc., and comes in a 1 mL single-dose syringe, with the NDC code 0409-1323-15. The lot number and expiration date are also provided on the packaging.*

FDA Label Image

Principal Display Panel (20 mg/mL Syringe Carton)

The text appears to be a set of instructions for using a syringe to administer an injection of Lidocaine, a medication used to relieve pain. The text also includes information about the concentration of Lidocaine in the injection and the lot number and expiration date of the medication. The manufacturer and distributor of the medication are also mentioned.*

FDA Label Image

Principal Display Panel (10 mg/mL Syringe Label)

This is a description of a medication called 1% Lidocaine HCI Injection, USP. It is available in a single-dose syringe containing 50 mg of the medication in 5 mL of liquid, at a concentration of 10 mg/mL. The medication is indicated for intravenous use to treat ventricular arrhythmias. It is a prescription medication and is distributed by Hospira RL-7650. The medication is manufactured and distributed in the USA, specifically in Lake Forest, Illinois. There is also information on the lot and expiry date of the medication.*

FDA Label Image

Principal Display Panel (10 mg/mL Syringe Carton)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.